XML 18 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Income Statement [Abstract]        
Molecular diagnostic testing $ 177.4 $ 173.0 $ 532.0 $ 516.6
Pharmaceutical and clinical services 13.1 7.0 35.4 16.6
Total revenue 190.5 180.0 567.4 533.2
Costs and expenses:        
Cost of molecular diagnostic testing 33.6 33.0 98.6 100.9
Cost of pharmaceutical and clinical services 6.6 3.3 18.7 8.1
Research and development expense 17.2 16.7 51.1 56.8
Selling, general, and administrative expense 90.5 91.3 267.8 269.4
Total costs and expenses 147.9 144.3 436.2 435.2
Operating income 42.6 35.7 131.2 98.0
Other income (expense):        
Interest income 0.3 0.1 0.5 0.3
Other 0.2 (0.3)   1.1
Total other income (expense): 0.5 (0.2) 0.5 1.4
Income before income tax 43.1 35.5 131.7 99.4
Income tax provision 10.5 14.1 42.1 37.9
Net income $ 32.6 $ 21.4 $ 89.6 $ 61.5
Earnings per share:        
Basic $ 0.46 $ 0.30 $ 1.28 $ 0.85
Diluted $ 0.44 $ 0.29 $ 1.22 $ 0.82
Weighted average shares outstanding:        
Basic 70.9 70.7 70.1 72.0
Diluted 73.5 73.9 73.2 75.1